Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Adalimumab/therapeutic use"'
Autor:
Michael B MacIsaac, Richard B. Gearry, Alyson L Ross, Mette Julsgaard, Peter R. Gibson, Emma Flanagan, Sally Bell, Stephanie Rowe
Publikováno v:
MacIsaac, M B, Julsgaard, M, Flanagan, E, Rowe, S, Ross, A L, Gearry, R B, Gibson, P R & Bell, S J 2022, ' Anti-TNFα Induction Therapy for Patients With Active Inflammatory Bowel Disease During Pregnancy : A Case Series ', Inflammatory Bowel Diseases, vol. 28, no. 4, pp. 652–655 . https://doi.org/10.1093/ibd/izab227
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4c17fc81b1537ba7bd9d6f3f027c4be
https://pure.au.dk/portal/da/publications/antitnf-induction-therapy-for-patients-with-active-inflammatory-bowel-disease-during-pregnancy(aa886956-5118-4df0-834c-a975b0d4a03d).html
https://pure.au.dk/portal/da/publications/antitnf-induction-therapy-for-patients-with-active-inflammatory-bowel-disease-during-pregnancy(aa886956-5118-4df0-834c-a975b0d4a03d).html
Autor:
Neil M.H. Graham, Zilberstein Moshe E, Jonathan Sadeh, Vibeke Strand, Cem Gabay, Jerome Msihid, Susan Boklage, Hubert van Hoogstraten, Toshio Kimura, Anita Boyapati, Gerd R Burmester
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Arthritis Research and Therapy, Vol. 22, No 1 (2020) P. 70
Arthritis Research & Therapy
Arthritis Research and Therapy, Vol. 22, No 1 (2020) P. 70
Arthritis Research & Therapy
Background Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a key role in the pathogenesis of rheumatoid arthritis. Sarilumab is a human monoclonal antibody that binds membrane-bound and soluble IL-6 receptor-α to inhibit IL-6 signalling. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::192a715ed44aff5f653df2a25c9dd684
http://link.springer.com/article/10.1186/s13075-020-02163-6
http://link.springer.com/article/10.1186/s13075-020-02163-6
Autor:
John D. Isaacs, Gisela Orozco, Anne Barton, Anthony G. Wilson, Darren Plant, Samantha L. Smith, Ann W. Morgan, Nisha Nair, Kimme L. Hyrich, James Oliver
Publikováno v:
Oliver, J, Nair, N, Orozco, G, Smith, S, Hyrich, K, Morgan, A W, Isaacs, J D, Wilson, A, BRAGGSS.,, Barton, A & Plant, D 2021, ' Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment ', Arthritis Research & Therapy, vol. 23, no. 1, 80 . https://doi.org/10.1186/s13075-021-02451-9
Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-9 (2021)
Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-9 (2021)
Background Despite the success of TNF-inhibitor therapy in rheumatoid arthritis treatment, up to 40% of patients fail to respond adequately. This study aimed to identify transcriptome-based biomarkers of adalimumab response in rheumatoid arthritis (R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0271121a2fdd885161e954dd80799ffa
https://pure.manchester.ac.uk/ws/files/200541427/s13075_021_02451_9.pdf
https://pure.manchester.ac.uk/ws/files/200541427/s13075_021_02451_9.pdf
Autor:
Caroline Trang, Salima Hacein-Bey Abina, Malin Ryner, Florian Deisenhammer, Manuel Comabella, Abiba Doukani, Philippe Broët, Anna Fogdell-Hahn, Julianne Duhaze, Hans-Peter Hartung, Clemens Warnke, Natacha Szely, Delphine Bachelet, Alessandra Vultaggio, Bernd C. Kieseier, Sebastian Spindeldreher, Olivier Brocq, Poul Erik Hyldgaard-Jensen, Michael Auer, Marc Pallardy, Matthieu Allez, Mary Birchler, Tom W J Huizinga, Yehuda Chowers, Yoram Bouhnik, Dorothea Buck-Martin, Elizabeth C. Jury, Amy Loercher, Dan Sikkema, Aude Gleizes, Tobias Derfuss, Jessica J Manson, Guillaume Cadiot, Claudia Sievers, Michael Khalil, Naoimh Donnellan, Raija L.P. Lindberg, Agnès Hincelin Mery, Badreddine Mohand Oumoussa, Enrico Maggi, Martin Soubrier, Kathleen Ingenhoven, Orhan Aktas, Sophie Tourdot, Xavier Montalban, Maria Nachury, Niek de Vries, Timothy P. Hickling, Christophe Richez, Bernhard Hemmer, Franck Carbonnel, Finn Sellebjerg, Jérôme Avouac, Petra Nytrova, Xavier Mariette, Anna Lauren, Signe Hässler, Pierre Dönnes, Eva Havrdova, Michael Guger, Claudia Mauri
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
PLoS Medicine
PLoS Medicine, 17(10). PUBLIC LIBRARY SCIENCE
PLoS Medicine, 2020, 17 (10), pp.e1003348. ⟨10.1371/journal.pmed.1003348⟩
Hässler, S, Bachelet, D, Duhaze, J, Szely, N, Gleizes, A, Hacein-Bey Abina, S, Aktas, O, Auer, M, Avouac, J, Birchler, M, Bouhnik, Y, Brocq, O, Buck-Martin, D, Cadiot, G, Carbonnel, F, Chowers, Y, Comabella, M, Derfuss, T, De Vries, N, Donnellan, N, Doukani, A, Guger, M, Hartung, H-P, Kubala Havrdova, E, Hemmer, B, Huizinga, T, Ingenhoven, K, Hyldgaard-Jensen, P E, Jury, E C, Khalil, M, Kieseier, B, Laurén, A, Lindberg, R, Loercher, A, Maggi, E, Manson, J, Mauri, C, Mohand Oumoussa, B, Montalban, X, Nachury, M, Nytrova, P, Richez, C, Ryner, M, Sellebjerg, F, Sievers, C, Sikkema, D, Soubrier, M, Tourdot, S, Trang, C, Vultaggio, A & ABIRISK Consortium 2020, ' Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease : A prospective multicohort study of the ABIRISK consortium ', PLoS Medicine, vol. 17, no. 10, e1003348 . https://doi.org/10.1371/journal.pmed.1003348
PLoS Medicine, Public Library of Science, 2020, 17 (10), pp.e1003348. ⟨10.1371/journal.pmed.1003348⟩
PLoS Medicine, Vol 17, Iss 10, p e1003348 (2020)
PLoS medicine, 17(10):e1003348. Public Library of Science
Universitat Autònoma de Barcelona
PLoS Medicine
PLoS Medicine, 17(10). PUBLIC LIBRARY SCIENCE
PLoS Medicine, 2020, 17 (10), pp.e1003348. ⟨10.1371/journal.pmed.1003348⟩
Hässler, S, Bachelet, D, Duhaze, J, Szely, N, Gleizes, A, Hacein-Bey Abina, S, Aktas, O, Auer, M, Avouac, J, Birchler, M, Bouhnik, Y, Brocq, O, Buck-Martin, D, Cadiot, G, Carbonnel, F, Chowers, Y, Comabella, M, Derfuss, T, De Vries, N, Donnellan, N, Doukani, A, Guger, M, Hartung, H-P, Kubala Havrdova, E, Hemmer, B, Huizinga, T, Ingenhoven, K, Hyldgaard-Jensen, P E, Jury, E C, Khalil, M, Kieseier, B, Laurén, A, Lindberg, R, Loercher, A, Maggi, E, Manson, J, Mauri, C, Mohand Oumoussa, B, Montalban, X, Nachury, M, Nytrova, P, Richez, C, Ryner, M, Sellebjerg, F, Sievers, C, Sikkema, D, Soubrier, M, Tourdot, S, Trang, C, Vultaggio, A & ABIRISK Consortium 2020, ' Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease : A prospective multicohort study of the ABIRISK consortium ', PLoS Medicine, vol. 17, no. 10, e1003348 . https://doi.org/10.1371/journal.pmed.1003348
PLoS Medicine, Public Library of Science, 2020, 17 (10), pp.e1003348. ⟨10.1371/journal.pmed.1003348⟩
PLoS Medicine, Vol 17, Iss 10, p e1003348 (2020)
PLoS medicine, 17(10):e1003348. Public Library of Science
Background Biopharmaceutical products (BPs) are widely used to treat autoimmune diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our knowledge of patient-related factors influencing the occurrence of antidru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f38afd466f71b9ab3ba9e7e10f54091
https://doi.org/10.1371/journal.pmed.1003348
https://doi.org/10.1371/journal.pmed.1003348
Autor:
Bent Deleuran, Oliver Hendricks, Holger Jon Møller, Line Dam Heftdal, Alice Christiansen, Bodil Arnbak, Anne Grethe Jurik, Stinne Ravn Greisen, Anne Gitte Loft, Berit Schiøttz-Christensen, René Østgård
Publikováno v:
Heftdal, L D, Loft, A G, Hendricks, O, Ashouri Christiansen, A, Schiøttz-Christensen, B, Arnbak, B, Jurik, A G, Østgård, R, Winding Deleuran, B, Møller, H J & Greisen, S R 2018, ' Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis ', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 78, no. 6, pp. 483-489 . https://doi.org/10.1080/00365513.2018.1500704
Heftdal, L D, Loft, A G, Hendricks, O, Ashouri Christiansen, A, Schiøttz-Christensen, B, Arnbak, B, Jurik, A G, Østgård, R, Winding Deleuran, B, Møller, H J & Greisen, S R 2018, ' Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis ', Scandinavian Journal of Clnical and Laboratory Investigation, vol. 78, no. 6, pp. 483-489 . https://doi.org/10.1080/00365513.2018.1500704
Heftdal, L D, Loft, A G, Hendricks, O, Ashouri Christiansen, A, Schiøttz-Christensen, B, Arnbak, B, Jurik, A G, Østgård, R, Winding Deleuran, B, Møller, H J & Greisen, S R 2018, ' Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis ', Scandinavian Journal of Clnical and Laboratory Investigation, vol. 78, no. 6, pp. 483-489 . https://doi.org/10.1080/00365513.2018.1500704
The chronic joint inflammation in axial spondyloarthritis (axSpA) is characterized by infiltration of activated macrophages. The haptoglobin-hemoglobin receptor CD163 and the mannose receptor CD206 are strongly expressed on M2c and M2a macrophages, r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f70fcdb90f5b06b8bf0159dc9b79660b
https://doi.org/10.1080/00365513.2018.1500704
https://doi.org/10.1080/00365513.2018.1500704
Autor:
Alexander A. Navarini, Curdin Conrad, Alessio Mylonas, Anne-Karine Lapointe, Jeremy Di Domizio, Olivier Demaria, Michel Gilliet, Cyrine Belkhodja, Lars E. French, Maxime Vernez
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Nature Communications
Nature communications, vol. 9, no. 1, pp. 25
Nature Communications
Nature communications, vol. 9, no. 1, pp. 25
Although anti-tumor necrosis factor (TNF) agents are highly effective in the treatment of psoriasis, 2–5% of treated patients develop psoriasis-like skin lesions called paradoxical psoriasis. The pathogenesis of this side effect and its distinction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbbc7decb248c10970a313c075620f0f
https://doaj.org/article/180fc992d72e4fcbbf1d606055e86015
https://doaj.org/article/180fc992d72e4fcbbf1d606055e86015
Autor:
Kristian Stengaard-Pedersen, Peter Junker, Anne Grethe Jurik, René Østgård, H Glerup, Bent Deleuran, Tue Wenzel Kragstrup, Merete Lund Hetland, Kim Hørslev-Petersen
Publikováno v:
Østgård, R, Glerup, H, Jurik, AG, Kragstrup, T W, Stengaard-Pedersen, K, Hetland, M L, Hørslev-Petersen, K, Junker, P & Deleuran, B 2017, ' Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients ', Scandinavian Journal of Rheumatology, vol. 46, no. 6, pp. 441-445 . https://doi.org/10.1080/03009742.2017.1286382
Østgård, R D, Glerup, H, Jurik, A G, Kragstrup, T W, Stengaard-Pedersen, K, Hetland, M L, Hørslev-Petersen, K, Junker, P & Deleuran, B W 2017, ' Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients ', Scandinavian Journal of Rheumatology, vol. 46, no. 6, pp. 441-445 . https://doi.org/10.1080/03009742.2017.1286382
Østgård, R D, Glerup, H, Jurik, A G, Kragstrup, T W, Stengaard-Pedersen, K, Hetland, M L, Hørslev-Petersen, K, Junker, P & Deleuran, B W 2017, ' Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients ', Scandinavian Journal of Rheumatology, vol. 46, no. 6, pp. 441-445 . https://doi.org/10.1080/03009742.2017.1286382
Objective: A reduction in haemoglobin level is a frequent complication among rheumatoid arthritis (RA) patients. Hepcidin has been linked to disturbed erythropoiesis. The objective of this study was to investigate the longitudinal changes in hepcidin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b025bb2d00cfd33f4b86ad060c2d9ef
https://doi.org/10.1080/03009742.2017.1286382
https://doi.org/10.1080/03009742.2017.1286382
Autor:
Jaime Ramos, Joana Roseira
Publikováno v:
Acta Médica Portuguesa, Vol 32, Iss 4, Pp 305-312 (2019)
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Inflammatory bowel disease activity is associated with adverse pregnancy outcomes. Anti-tumor necrosis factor α therapy is often required to treat flares and to maintain disease remission. However, there are concerns regarding treatment with these a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::586e07d2a85c618ef8ffd90a3b25f0ff
https://hdl.handle.net/10400.17/3271
https://hdl.handle.net/10400.17/3271
Autor:
Kristian Stengaard-Pedersen, Torkell Ellingsen, Hanne Merete Lindegaard, Peter Junker, Anette Jørgensen, Julia S. Johansen, Lykke Midtbøll Ørnbjerg, Tine Lottenburger, Rebecca Bolce, Cecilie Heegaard Brahe, Asta Linauskas, X Wang, Nadine Defranoux, Eric H. Sasso, Palle Ahlquist, Johnny Lillelund Raun, Mikkel Østergaard, Sophine B. Krintel, Ib Hansen, Christian Gytz Ammitzbøll, Kim Hørslev-Petersen, Annette Schlemmer, Merete Lund Hetland, Mette Yde Dam
Publikováno v:
Brahe, C H, Østergaard, M, Johansen, J S, Defranoux, N, Wang, X, Bolce, R, Sasso, E, Ørnbjerg, L, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Lottenburger, T, Ammitzbøll, C, Jørgensen, A, Krintel, S, Raun, J & Hetland, M 2019, ' Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis : a post-hoc study of the OPERA trial ', Scandinavian Journal of Rheumatology, vol. 48, no. 1, pp. 9-16 . https://doi.org/10.1080/03009742.2018.1464206
Brahe, C H, Østergaard, M, Johansen, J S, Defranoux, N, Wang, X, Bolce, R, Sasso, E H, Ørnbjerg, L M, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Lottenburger, T, Ammitzbøll, C, Jørgensen, A, Krintel, S B, Raun, J & Hetland, M L 2019, ' Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis : a post-hoc study of the OPERA trial ', Scandinavian Journal of Rheumatology, vol. 48, no. 1, pp. 9-16 . https://doi.org/10.1080/03009742.2018.1464206
Brahe, C H, Østergaard, M, Johansen, J S, Defranoux, N, Wang, X, Bolce, R, Sasso, E H, Ørnbjerg, L M, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Lottenburger, T, Ammitzbøll, C, Jørgensen, A, Krintel, S B, Raun, J & Hetland, M L 2019, ' Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis : a post-hoc study of the OPERA trial ', Scandinavian Journal of Rheumatology, vol. 48, no. 1, pp. 9-16 . https://doi.org/10.1080/03009742.2018.1464206
OBJECTIVES: Measurement of serum biomarkers at disease onset may improve prediction of disease course in patients with early rheumatoid arthritis (RA). We evaluated the multi-biomarker disease activity (MBDA) score and early changes in MBDA score for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea3dba9f21c328597c172b320aec3e4d
https://pubmed.ncbi.nlm.nih.gov/29985080
https://pubmed.ncbi.nlm.nih.gov/29985080
Autor:
Achuthan Aruljothy, Talat Bessissow, Alain Bitton, Sophie Restellini, Gary Wild, Peter L. Lakatos, Waqqas Afif, Haya Aziz, Che-Yung Chao, Omar Kherad
Publikováno v:
Inflammatory Bowel Diseases, Vol. 24, No 7 (2018) pp. 1531-1538
Background Managing loss of response (LOR) in Crohn's disase (CD) patients remains challenging. Compelling evidence supports therapeutic drug monitoring (TDM) to guide management in patients on infliximab, but data for other biologics are less robust
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f5a991b685e85e4ce1487a560c2c916
https://pubmed.ncbi.nlm.nih.gov/29668893
https://pubmed.ncbi.nlm.nih.gov/29668893